IMMUNOLOGY INFUSION REFERRAL FORM



PATIENT INFOR	MATION				PRESCRIBE	R IN	ORMAT	ION			
Last Name	First Name		DOB	ī [Name of Contact Sending Referral			Title			
Gender	Last 4 SSN		Primary Language		Preferred Contact Method (check one)	□ Ema □ Pho	Phone		ontact Email		
Address					Office Phone Office Fax			Office Fax			
City State		ZIP		Practice / Facility Name							
Email					Address						
Home Phone Work Phone			Cell Phone		City			State	ZIP		
Primary Contact Method □ Cell Phone □ Home Phone □ Work Phone (check one) □ Text □ Email □ Primary Caregiver □ DO NOT CONTACT					Prescriber Name / Specialty						
Primary Caregiver/Alt Contact Name (If applicable)					Prescriber State License #				DEA #		
Caregiver/Alt Contact Email Careg			giver/Alt Contact Phone		NPI#				Medicaid UPIN #		
INSURANCE INF	ORMATI	ON									
Insurance Provider			Plan ID #		Eligible for Medicare						
BIN#: PCN#:			RX Group#:		Prescription Card ☐ Yes If yes, list carrier (check one) ☐ No						
Insured's Name			Relationship to Patient	7 i	Please include a copy of the front and back of insurance card				k of insurance card.		
CLINICAL INFO	RMATION	ı									
Prescription Type	☐ Naïve/New Start ☐ Therapy Restart ☐ Existing Treatment		Therapy Start Date		Patient Height (cm/in) Patient Weigh		nt (kg/lbs)	(kg/lbs) Date Obtained			
Sample/Starter Product Provided? □ Yes □ No	If yes, Provide		Date Sample Provided		Ship to Address			er's Office			
Allergies □ NKDA □ Drug Allergies (olease list)				ICD-10 Codes	□ D83 □ D81	.0 Congenital H .9 CVID (unspec .9 SCID (unspec er	cified) cified)			
Therapies Tried and Failed (pl	ease list medica	tions)									
Concurrent Medications											

PRESCRIPTIONS

Prescriber Signature

Supervising Physician Signature (Dispense as Written)

			Name	DOB									
PRESCRIPTION INFORMATION													
1EDICATION	ROUTE	DOSE/STRENGTH	DIRECTIONS	QTY	REFILLS								
I Asceniv™ 10% I Bivigam® 10% I Gammagard® Iiquid 10% I Gammagard® S/D 5% I Gammaded™ 10% I Gammahed™ 10% I Gammaplex® 5% I Gammaplex® 10% I Gammaplex® 10% I Gammaplex® 10% I Hizentra 20% I Octagam® 10% I Privigen® 10% I Xembify	□ Peripheral □ Central □ Port □ Subcutaneous	Infuse grams OR grams per kg OR mgper kg intravenously every weeks Divide total dose over days (where clinically appropriate, round to the nearest vial size)	Rate protocol: Titrate initial and maintenance infusions per manufacturer's product labeling Infusion method: Gravity Pump	□3 months □6 months □1 year									
Normal Saline DSW	□IV	□3 mL □5 mL	☐ Before and after infusion ☐	□ 1 month □ 3 months	□1 year								
Heparin 10 units/mL Heparin 100 units/mL	□IV	□3 mL □5 mL	□ After infusion	□ 1 month □ 3 months	□1 year								
Diphenhydramine	□PO □IV □IM	□ 25 mg □ 50 mg	☐ After infusion ☐ PRN Allergic Reaction:	□With each infusion	□1 year								
l Acetaminophen	□РО	□ 325 mg □ 500 mg □ 650 mg □ 1 gm □	□ Pre-Med:	□With each infusion	□1 year								
l Epinephrine	□IM □SQ	□ Adult 1:1000, 0.3 mL (>30kg/>66lbs) □ Peds 1:2000, 0.3 mL (15-30kg/33-66lbs)	□ PRN Anaphylaxis □ Repeating Dose:	□Once	□1 year								
Other:													
Vascular Access Method	□ peripheral	□ central □ other:		'									
h Oud au				Tota	l RXs _								
edles, syringes, ancillary supped edle, syringes, etc). If shipped	olies and medical equi d to physician's office,	pment necessary to establish access and physician accepts on behalf of patient fo	general status and response to therapy. Dispense 1 month of drug administer medication. Prescription to include all necessary anci or administration in office.	llary supplies									

**The information contained in this document will become a legal prescription. Follow all state Medical Board guidelines when completing, inclusive of guidelines that pertain to the number of prescriptions allowed on a single prescription form. If more than one page is required, make additional copies. Use state board mandated language for dispensing brand name medications or generic substitution and follow physician signature requirements.

Date

Date

Prescriber Authorization (No stamps. Signature and date must be completed in prescriber's handwriting.)

Confidentiality Statement: This message is intended only for the individual or entity to which it is addressed. It may contain information which may be proprietary and confidential. It may also contain privileged, confidential information which is exempt from disclosure under applicable laws, including the Health Insurance Portability and Accountability Act (HIPAA). If you are not the intended recipient, please note that you are strictly prohibited from disseminating or distributing this information (other than to the intended recipient) or copying this information. If you received this communication in error, please notify the sender immediately at the address and telephone number set forth herein and obtain instructions as to proper destruction of the transmitted material.